Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer Institute

Updates in Multiple Myeloma in 2024: From Bench to BedsideПодробнее

Kenneth C. Anderson - Multiple myeloma cured in 2030: what are the next steps?Подробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

Kenneth C. Anderson tells about Multiple myeloma cured in 2030: what are the next steps?Подробнее

Si-Han Chen - Dana-Farber Targeted Degradation Webinar SeriesПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Future perspectives on CAR-T therapy for multiple myelomaПодробнее

Myeloma 101: Diagnosis, Prognosis & Risk | Dana-Farber Cancer InstituteПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Updates on AL Amyloidosis Treatment: What is New in 2023 | Dana-Farber Cancer InstituteПодробнее

The Evolving Role of Quadruplet Therapy in Newly Diagnosed Multiple Myeloma: Jacob Laubach, MDПодробнее

2019 Multiple Myeloma Symposium | Managing Bone DiseaseПодробнее

Hicks Harris Ferguson Multiple Myeloma Virtual SeminarПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MDПодробнее

Diagnosis and Risk Assessment In Multiple MyelomaПодробнее

Dana-Farber’s Presidential Symposium Breakout: Discovery ScienceПодробнее

Current and Future Treatment of Multiple MyelomaПодробнее

Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MDПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее